PLUS

HEADLINES TREATMENT REGIMENS FROM THE ADVISORY BOARD PUBLISHERS ALLIANCE TOOLS MULTIMEDIA CME

FDA Approves Ibrutinib for CLL

Share this article:
New Drug Approved for Refractory or Relapsed Mantle Cell Lymphoma
New Drug Approved for Refractory or Relapsed Mantle Cell Lymphoma

The United States Food and Drug Administration (FDA) today announced its approval of ibrutinib (Imbruvica®) for treatment of chronic lymphocytic leukemia (CLL) in patients who have received at least one prior therapy, according to a press release.

The FDA's decision expands the indication for ibrutinib, which received accelerated approval from the FDA in November 2013 to treat patients with mantle cell lymphoma who have received at least one prior therapy.

Similarly, for the CLL indication, ibrutinib was granted priority review and orphan-product designation.

RELATED: Ibrutinib: Second FDA-Approved Drug with Breakthrough Therapy Designation for MCL

The FDA based their accelerated approval of ibrutinib for CLL on results of a clinical study involving 48 participants who had previously received an average of four therapies and were diagnosed an average of 6.7 years before study enrollment. Researchers administered 420 mg of ibrutinib orally until unacceptable toxicity occurred or until the disease progressed.

According to the release, the cancer shrunk in 58% of participants after treatment, and duration of response ranged from 5.6 to 24.2 months; however, results did not firmly establish a correlation between treatment and improvement in survival or disease-related symptoms.

RELATED: Hematologic Cancers Resource Center

Common side effects of ibrutinib included thrombocytopenia, diarrhea, bruising, neutropenia, anemia, upper respiratory infection, musculoskeletal pain, rash, pyrexia, constipation, peripheral edema, arthralgia, nausea, stomatitis, sinusitis, and dizziness.

“Today's approval provides an important new treatment option for [patients with CLL] whose cancer has progressed despite having undergone previous therapy,” Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, said in the release. “The FDA completed its review of Imbruvica's new indication under the agency's accelerated approval process, which played a vital role in rapidly making this new therapy available to those who need it most.”

Share this article:

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Hematologic Cancers

Immune Therapy Induces Acute Lymphoblastic Leukemia (ALL) Remission

Immune Therapy Induces Acute Lymphoblastic Leukemia (ALL) Remission

Major short-term risk is cytokine release syndrome for acute lymphoblastic leukemia (ALL).

For Patients With Multiple Myeloma, DTP3 May Be Effective

For Patients With Multiple Myeloma, DTP3 May Be ...

A novel cancer drug called DTP3 has effectively killed myeloma cells in human cells and mice during laboratory tests.

Leo1 Gene Increases Risk for Developing Acute Myelogenous Leukemia (AML)

Leo1 Gene Increases Risk for Developing Acute Myelogenous ...

A gene called Leo1 leads to an increased risk for developing acute myelogenous leukemia (AML).